Efficacy and safety of anlotinib combined with ¹²⁵I seed implantation for iodine-refractory thyroid cancer.

ABSTRACT:

Background and objective

Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) remains challenging to treat due to a lack of effective therapies. This study aimed to evaluate the efficacy and safety of combining anlotinib with iodine-125 (¹²⁵I) seed implantation in patients with RAIR-DTC.

Methods and materials

We retrospectively compared three treatment groups in 52 patients with advanced RAIR-DTC: anlotinib monotherapy (Group A, n = 14), ¹²⁵I seed brachytherapy monotherapy (Group B, n = 25), and combined therapy (Group C, n = 13). Clinical outcomes including local progression-free survival (LPFS), overall survival (OS), tumor response, serum thyroglobulin (Tg) levels, and adverse events were analyzed.

Results

As of

SUBMITTER: Chen Z 

PROVIDER: S-EPMC12411173 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature